Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nacresertib - Shanghai Meiyue Biotechnology

Next Previous
Drug Profile

Nacresertib - Shanghai Meiyue Biotechnology

Alternative Names: ABBV-848; MY-004; MY-004567

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Meiyue Biotechnology Development
  • Developer AbbVie; Shanghai Meiyue Biotechnology Development; Wuhan Createrna Science and Technology
  • Class Alcohols; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclohexanes; Ethers; Indazoles; Pyridines; Pyridinium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action IRAK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I IgA nephropathy

Most Recent Events

  • 13 Aug 2026 Phase-I clinical trials in IgA nephropathy in China (PO), prior to August 2026 (Wuhan Createrna Science and Technology pipeline, August 2026)
  • 24 Jun 2026 Chemical structure information added
  • 23 Jun 2026 AbbVie initiates a phase I pharmacokinetic trial (In volunteers) in the US (PO, Tablet) (NCT07649954)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top